Patients must have high-grade bladder cancer as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification
Patients with low grade glioma patients (World Health Organization [WHO] grades I and II) are not eligible
Neuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient must not have Burkittâ€™s lymphoma/leukemia based on the World Health Organization (WHO) criteria
Dose Escalation - Relapsed or refractory AML (excluding acute promyelocytic leukemia) or PDCN, based on World Health Organization Classification. All patients enrolled on this study will have CD123+ disease.
Diagnosis of one of the following histologic subtypes of PTCL, pathologically-confirmed, as defined by the World Health Organization:
Diagnosis of AML per World Health Organization (WHO) criteria (except acute promyelocytic leukemia)
Morphologically confirmed diagnosis of MDS or MDS/MPN in accordance with World Health Organization (WHO) diagnostic criteria
Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) which is relapsed or refractory after failing at least 1 regimen and is not a candidate for established salvage treatment regimens
Documented pathological evidence of MDS as defined by the World Health Organization (WHO) criteria
Have histologically confirmed World Health Organization (WHO) grade II or III meningioma that is progressive or recurrent; metastatic meningiomas are allowed; participants must have failed maximal safe resection and radiation therapy
Single agent (SA) Dose Escalation: Histologically or cytologically proven acute leukemia or high-risk MDS as defined by the World Health Organization (WHO) criteria and IPSS-R, respectively, that is relapsed or refractory (R/R) to standard therapy or for whom standard treatments are contraindicated, OR
World Health Organization (WHO) performance status =< 2
Diagnosis of PTCL according to the most recent edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic or Lymphoid Tissues, as follows:
Refractory or relapsed lymphoma (per World Health Organization (WHO) Classification system)
Diagnosis of de novo or secondary myelodysplastic syndrome (MDS), including chronic myelomonocytic leukemia, as defined by the 2008 World Health Organization classification system
A diagnosis of acute promyelocytic leukemia as defined by the 2008 World Health Organization classification system
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria with ?20% bone marrow blasts based on histology or flow cytometry
Subject has documented, histologically locally confirmed, previously untreated CD20+ DLBCL (NOS) per World Health Organization (WHO) classifications (Swerdlow, 2008).
A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.
RAEB-1 per World Health Organization (WHO) MDS criteria (5% to <10% BM blasts)
World Health Organization (WHO) performance status equal to 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)
Diagnosis of CMML as defined by the World Health Organization (WHO) criteria.
Histologically confirmed atypical meningioma, World Health Organization (WHO) grade II, Simpson grade 4-5 that has been either subtotally resected or biopsied; OR
RR DLBCL per the 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid tumors (Swerdlow et al, 2008).
Diagnosis of a b-cell malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
World Health Organization (WHO)-confirmed acute myeloid leukemia (AML)
Eastern Cooperative Oncology Group (ECOG) (World Health Organization [WHO]) performance status 0 or 1 or 2
Patients with pathology confirmed newly diagnosed World Health Organization (WHO) grade IV glioma
Histologically confirmed diagnosis of World Health Organization grade IV malignant glioma
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2
A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification.
Must have pathologically documented, and definitively diagnosed World Health Organization (WHO) grade 4, glioblastoma
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Diagnosis of recurrent or progressive histologically confirmed World Health Organization (WHO) grade I-III meningioma which has failed maximal safe resection and radiation therapy
Diagnosis of AML by World Health Organization (WHO) criteria. Patients with high risk myelodysplastic syndrome (MDS) as defined by the presence of >= 10% blasts are also eligible at the discretion of the principal investigator
Patients with a diagnosis BPDCN according to World Health Organization (WHO) classification confirmed by hematopathology;
Patients must have histologically confirmed ND or R/R PTCL defined according to the 2016 World Health Organization (WHO) classification criteria, with no accepted curative options\r\n* Patients with extranodal natural killer (NK)/T-cell lymphoma may only be allocated to treatment Arm D
Participant must have histological confirmation of Acute Myeloid Leukemia (AML) by World Health Organization criteria, be ineligible for intensive induction chemotherapy and either be:
Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria
Diagnosis of MDS as defined by the World Health Organization (WHO) diagnostic criteria
Subjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by World Health Organization (WHO) classification
AML according to world health organization (WHO) criteria (i.e. bone marrow blasts >20%)
Patients with World Health Organization (WHO) class III or IV pulmonary hypertension
Histologically documented diagnosis (based on the 2008 World Health Organization [WHO] Classification) of one of the following:
Pathologically documented, and definitively diagnosed recurrent World Health Organization (WHO) Grade IV astrocytoma (GBM).
Subjects must have histologically or cytologically confirmed World Health Organization (WHO) grade 4 glioma for which a clinically indicated tumor resection is planned
Subjects must have histologically confirmed diagnosis of World Health Organization (WHO) grade III or IV malignant glioma
For Part 1 of the study, participants must have histopathologically confirmed diagnosis of R/R, DLBCL, FL, MZL/MALT, MCL, or other Sponsor approved NHL subtypes according to the World Health Organization (WHO) classification 2008 for which standard measures do not exist or are no longer effective.
Documented/confirmed first/second refractory/relapsed AML using World Health Organization classification, except acute promyelocytic leukemia
World Health Organization (WHO) performance status 0-2
World Health Organization Performance Status of 0 to 1.
Patients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms
Diagnosis of 1) AML (World Health Organization [WHO] classification definition of >= 20% blasts), or 2) high risk MDS (defined as the presence of 10% blasts)
History of AML according to World Health Organization (WHO) classification
Histologic confirmation of thymic carcinoma (World Health Organization [WHO] classification)
Mature T-cell non-Hodgkin lymphoma (see World Health Organization [WHO] for specific malignancies)\r\n* First CR\r\n* Relapse after greater than or equal to 1 prior regimen
Must have a histopathologically documented diagnosis of primary or secondary AML (excluding acute promyelocytic leukemia), as defined by World Health Organization (WHO) criteria (Jaffe et al, 2001), for whom no standard therapies are anticipated to result in a durable remission according to the clinical judgment of the principal investigator, or who refuses standard therapies (phase 1b and 2).
World Health Organization (WHO) performance status 0-2
Diagnosis of AML (World Health Organization [WHO] classification definition of >= to 20% blasts)
Diagnosis of myelodysplastic syndrome (MDS) confirmed within 10 weeks prior to study entry according to World Health Organization (WHO) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
Performance status (World Health Organization [WHO]/Eastern Cooperative Oncology Group [ECOG] scale) 0-2
Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
Histologically confirmed mantle cell lymphoma classified according to World Health Organization (WHO) criteria confirmed at MSKCC
History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts ?20%).
World Health Organization (WHO) performance status =< 2
Myelodysplastic syndrome as defined by World Health Organization (WHO) criteria
Histologically confirmed diagnosis of World Health Organization (WHO) I-III meningiomas and hemangiopericytomas
Diagnosis of either PMF per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms, PPV-MF or PET-MF per the IWG-MRT
Confirmed diagnosis of de novo AML according to World Health Organization (WHO) 2016 classification
Confirmed diagnosis of AML according to World Health Organization (WHO) 2016 classification
Histologically or cytologically documented diagnosis of MDS according to the World Health Organization (WHO) classification (Vardiman 2009, Arber 2016) with >5% and <20% bone marrow blasts by morphology and a peripheral white blood cell (WBC) count of <20,000/?L
Cytologically or histologically confirmed diagnosis of MDS or CMML according to the 2008 World Health Organization (WHO) classification.
Diagnosis of AML per World Health Organization criteria
The subject must have histological confirmation of GBM (World Health Organization [WHO] grade IV)
Subject has morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
Histologically confirmed diagnosis of World Health Organization grade III or IV malignant glioma
Morphologically confirmed new diagnosis of AML in accordance with World Health Organization (WHO) diagnostic criteria
Newly diagnosed and histologically confirmed supratentorial World Health Organization (WHO) Grade IV astrocytoma status-post maximally achievable resection
Patients must have histologically or cytologically confirmed AML according to the World Health Organization (WHO) criteria
Diagnosis of acute myeloid leukemia (AML) as defined by the World Health Organization
Documented diagnosis of primary myelofibrosis according to World Health Organization (WHO) criteria or post polycythemia vera (PV) myelofibrosis or post essential thrombocythemia (ET) myelofibrosis as per IWG-MRT criteria
A diagnosis of ET or PV shall be made in accordance with the World Health Organization (WHO) (2008) criteria (Swerdlow 2008)
Diagnosis of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as documented by medical records and with histology based on criteria established by The World Health Organization (WHO):
Relapsed or refractory CD25-positive AML [per World Health Organization (WHO)].
Relapsed or refractory CD25-positive ALL [per World Health Organization (WHO)].
Diagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-1
Diagnosis of B-cell iNHL, DLBCL, MCL, or CLL as documented by medical records and with histology based on criteria established by the World Health Organization
Age ? 18 years at the time of signing the informed consent form. 8. Central confirmation of diagnosis of previously untreated primary or secondary Myelodysplastic syndromes (MDS) as per World Health Organization (WHO) classification. Results of central pathology review are required prior to receiving the first dose of IP.
World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Myelodysplastic Syndrome (MDS) according to the World Health Organization (WHO) 2008 classification
World Health Organization (WHO) risk score 0-6
A diagnosis of SM per 2008 World Health Organization (WHO) criteria; patients with ASM and MCL, or SM-AHNMD are required to have at least one of the eligible organ damage findings as defined by the international consensus response criteria (Gotlib, 2013)
A diagnosis of systemic mastocytosis (SM) per 2008 World Health Organization (WHO) Criteria
Subject has a diagnosis of previously-untreated AML according to World Health Organization (WHO) classification [Swerdlow et al, 2008] as determined by pathology review at the treating institution.
In Part 1, diagnosis of myelodysplastic syndrome (MDS) according to World Health Organization (WHO) criteria
World Health Organization (WHO) performance status of 0, 1, or 2
Performance status (World Health Organization [WHO] scale) < 2
World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at least 3 months
World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
Diagnosis of CLL meeting criteria established in the World Health Organization (WHO) classification of hematologic disorders
JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by World Health Organization [WHO] diagnostic criteria)
World Health Organization (WHO) Performance Status of 0 or 1
World Health Organization Performance Status of 0 to 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
Patients with thymic carcinoma (formerly World Health Organization [WHO] type C)
World Health Organization (WHO) performance status 0-1
World Health Organisation (WHO) Performance Status of 0 to 1.
World Health Organisation (WHO) Performance Status of 0 or 1
Diagnosis of acute myelogenous leukemia (AML) according to World Health Organization (WHO) criteria;
Diagnosis of histologically confirmed GBM (World Health Organization [WHO] grade IV)
Patients must have a diagnosis of CLL/SLL or B-cell prolymphocytic leukemia, as defined by the World Health Organization (WHO)
Age >= 70, or age >= 60 ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization classification
World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
Confirmed diagnosis of CMML using the World Health Organization (WHO) classification
primary myelofibrosis (PMF) per the revised World Health Organization (WHO) criteria
Subject must have histologically documented diagnosis of non-Hodgkin's lymphoma as defined by a B-cell neoplasm in the World Health Organization classification scheme except as noted in exclusion criteria.
Patients must have a World Health Organization performance status =< 2
Patients with World Health Organization performance status of 3 or 4
Must have measurable disease by modified World Health Organization (WHO) criteria
Diagnosis of essential thrombocythemia according to revised World Health Organization (WHO) 2016 criteria.
World Health Organization (WHO) performance status 0-2
Subjects with cytologically/histologically confirmed MDS according to the World Health Organization (WHO) 2008 classification.
Patients with a new diagnosis of histologically confirmed (according to World Health Organization [WHO] classification 2008) acute myeloid leukemia (either primary or secondary AML) are included
Patients must have a previous morphologically confirmed diagnosis of AML based on World Health Organization (WHO) criteria
Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
World Health Organization (WHO) Performance Status (PS) ? 2
Frozen section diagnosis of World Health Organization (WHO) grade IV glioma, confirmed with permanent section and immunopositive for IGF-1R
A diagnosis of acute myeloid leukemia (AML) based on World Health Organization (WHO) classification (>= 20% myeloblasts in peripheral blood or bone marrow)
Patients must have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL) of non-GCB subtype, established according to the World Health Organization (WHO) criteria that has been tested for the MyD88 L265P mutation.
Eastern Cooperative Oncology Group (World Health Organization) performance status of 0 or 1
Newly-diagnosed AML by World Health Organization (WHO) criteria (>= 20% myeloid blasts by morphology in either blood or marrow)
Subject is defined as morphologically documented primary or secondary AML by the World Health Organization (WHO) criteria (2008) and fulfills one of the following:
Biopsy-proven diagnosis of cHL (regardless of Hodgkin/Reed-Stemberg [HRS] cell cluster of differentiation [CD]20 expression) per the World Health Organization classification criteria; lymphocyte predominant histology is excluded
The patient has a diagnosis of AML according to World Health Organization (WHO) criteria.
Have histologically or cytologically confirmed recurrent Grade 2 or 3 LGG (oligodendroglioma or astrocytoma according to World Health Organization 2016 classification).
Diagnosis of histopathologically confirmed B-cell NHL (as per the World Health Organization [WHO] 2016 classification) including WM/LPL.
Documentation that the participant has met the revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera (PV)
Indolent NHL subtypes defined according to World Health Organization guidelines:
Pre-study World Health Organization (WHO) performance status of 0, 1, or 2
The patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status 0-2
Patient with diagnosis of glioma, or other World Health Organization (WHO) grade II - IV primary brain tumor
Patients must have histologically confirmed World Health Organization (WHO) grade 2 or 3 gliomas
Diagnosis of B cell non-Hodgkin lymphoma confirmed by World Health Organization (WHO) criteria
Patients with newly diagnosed World Health Organization (WHO) grade III or IV astrocytoma who will undergo concomitant radiation and temozolomide followed by adjuvant temozolomide
Receiving health care primarily through an health maintenance organization (HMO)
Attained menopause as defined by World Health Organization Criteria
Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status of 0-2
Patient has Karnofsky score >= 50 or World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) =< 2 if >= 16 years of age
Patients must have a World Health Organization performance status of =< 2
Score of >= 8 on the World Health Organization (WHO) Alcohol Use Disorders Identification Test (AUDIT, sensitivity of 0.8)
Tumor pathology: suspected or confirmed newly diagnosed or recurrent malignant gliomas World Health Organization (WHO) grade IV
Karnofsky performance status of ? 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status (KPS) ? 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] 0, 1, or 2)
Karnofsky performance status (KPS) ? 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] 0, 1, or 2)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of 50 or greater (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/ World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status or Lansky play scale status of >= 60 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis per World Health Organization 2008 criteria
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status or Lansky Play Scale status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status of > 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Karnofsky performance status or Lansky Play Scale status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).
